D4F prophylaxis enables redox and energy homeostasis while preventing inflammation during hypoxia exposure - 19/12/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 10 |
| Iconographies | 5 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | D4F was administered at 10 mg/kg BW for 7 days (i.p.) prior to hypoxia exposure. |
• | D4F prophylaxis strengthened redox and energy homeostasis during hypoxia. |
• | D4F prophylaxis also subdued hypoxia-induced inflammation. |
• | The positive effects of D4F on lipid metabolism were partially reversed in normoxia. |
Abstract |
Apo-A1 is correlated with conditions like hyperlipidemia, cardiovascular diseases, high altitude pulmonary edema and etc. where hypoxia constitutes an important facet.Hypoxia causes oxidative stress, vaso-destructive and inflammatory outcomes.Apo-A1 is reported to have vasoprotective, anti-oxidative, anti-apoptotic, and anti-inflammatory effects. However, effects of Apo-A1 augmentation during hypoxia exposure are unknown.In this study, we investigated the effects of exogenously supplementing Apo-A1-mimetic peptide on SD rats during hypoxia exposure. For easing the processes of delivery, absorption and bio-availability, Apo-A1 mimetic peptide D4F was used. The rats were given 10 mg/kg BW dose (i.p.) of D4F for 7 days and then exposed to hypoxia. D4F was observed to attenuate both oxidative stress and inflammation during hypoxic exposure. D4F improved energy homeostasis during hypoxic exposure. D4F did not affect HIF-1a levels during hypoxia but increased MnSOD levels while decreasing CRP and Apo-B levels. D4F showed promise as a prophylactic against hypoxia exposure.
Le texte complet de cet article est disponible en PDF.Keywords : D4F, Apo-A1, Prophylaxis, Hypoxia, Inflammation, Energy homeostasis
Plan
Vol 133
Article 111083- janvier 2021 Retour au numéro
Article précédent
- Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice
- Youbin Liu, Ying Fan, Jinglong Li, Meng Chen, Anyong Chen, Dahao Yang, Xue Guan, Yong Cao
- Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells
- Sandipan Datta, Thomas Sears, Gino Cortopassi, Kevin Woolard, James M. Angelastro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?